Hims Has a Stock? Yes. And They Just Dropped Their Q1 Earnings.

May 5th, 2025 — RBC Network

In case you thought Hims & Hers was just that company with hair loss ads haunting your podcast breaks— They’re also a publicly traded company (NYSE: HIMS), and yes, they really have a stock.

As of today, they’ve officially dropped their Q1 2025 earnings report, and the numbers are buzzing more than your electric trimmer.

First, what is Hims?

In short, it’s a telehealth platform built for the modern crowd. They sell treatments for erectile dysfunction, anxiety, depression, hair loss, and more recently, weight loss.

Now the earnings.

Revenue for Q1 2025 landed right in the target zone: between $520 million and $540 million, according to analyst projections. While we await exact figures from the earnings call later today, the real eye-catcher is their expected adjusted EBITDA, which ranges from $55 million to $65 million. Not bad for a company selling confidence and health.

This growth comes off a hot 2024, where Hims reported $1.5 billion in revenue—a 69% jump from the year before. Key to their momentum: a strategic partnership with pharma heavyweight Novo Nordisk, giving customers streamlined access to the weight-loss juggernaut Wegovy.

Still, not all stockholders are chill. Despite the revenue highs, HIMS stock took a 20% plunge earlier this year after one earnings report didn’t quite seduce Wall Street. Today, the stock was trading around $40.33, with some ups and downs baked into the pre-call jitters.

The takeaway?

Hims is more than cheeky branding and Instagram-friendly packaging—it’s a serious player in digital health, pushing boundaries in how we access care. And as they move deeper into high-stakes spaces like weight loss, mental health, and prescription meds, they’re proving that yes, telehealth isn’t just a pandemic fling—it might be here for good.

So next time you hear a friend say, “Wait, Hims has a stock?”—you can confidently say: “Yes, and it might just be one of the glow-up stories of the decade.”

——-update——

May 6th, 2025

Hims & Hers reported strong Q1 2025 earnings on May 5, beating analyst expectations with $278.2 million in revenue, a 46% year-over-year increase. Net income hit $11.3 million.

The platform added 169,000 new subscribers, reaching 1.7 million total. Shares surged over 25% post-announcement, fueled by growing demand for mental health and weight-loss treatments. CEO Andrew Dudum cited strong margins and product expansion as key drivers.

Tate Chronicles

Let Your Voice Be Heard

#LoveTheChase